Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Key inclusion criteria~* \>=18 years of age~* Has had RA for \>=6 months and was not diagnosed before 16 years of age~* Has active disease, as defined by having both:\*~  * \>=6/68 tender/painful joint count (TJC), and~ * \>=6/66 swollen joint count (SJC)~* Has at least 1 bone erosion present on hand/wrist or foot radiographs~* Has had an inadequate response to MTX, despite currently taking MTX 15-25 mg/week\*\* oral or injected~  * If surgical treatment of a joint has been performed, that joint cannot be counted in the TJC or SJC.~    * A lower dose of 7.5 mg/week is acceptable if reduced for reasons of intolerance to MTX or per local requirement.~Key exclusion criteria~* Has had any active and/or recurrent infections (excluding recurrent fungal infections of the nail bed) or has required management of acute or chronic infections.~* Has received prior treatment with an antagonist of GM-CSF or its receptor or Janus kinase (JAK) inhibitors (either experimental or approved)~* Has received prior treatment with a biologic Disease-modifying antirheumatic drug (DMARD) which has been discontinued due to an inadequate response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK3196165 90mg + MTX (Type: EXPERIMENTAL): Participants received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with methotrexate (MTX).
- GSK3196165 150mg + MTX (Type: EXPERIMENTAL): Participants received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with MTX.
- Tofacitinib 5mg + MTX (Type: ACTIVE_COMPARATOR): Participants received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with MTX plus placebo injection weekly to maintain the blind for 52 weeks.
- Placebo + MTX and GSK3196165 90mg + MTX (Type: PLACEBO_COMPARATOR): Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with MTX until Week 52.
- Placebo + MTX and GSK3196165 150mg + MTX (Type: PLACEBO_COMPARATOR): Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with MTX until Week 52.
- Placebo + MTX and Tofacitinib 5mg + MTX (Type: PLACEBO_COMPARATOR): Participants received Placebo capsule weekly in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with MTX plus placebo injection to maintain the blind for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete